A European report emphasizes the importance of considering cardiovascular risks in COVID-19 treatment, recommending repeat vaccination, early rehabilitation, and comprehensive long-term care to mitigate heart-related complications and address the growing burden of long COVID.
Recent research suggests that a daily dose of 100 mg aspirin may reduce cardiovascular risks in individuals with high Lp(a) levels, a significant heart disease risk factor, but the decision to use aspirin should consider bleeding risks. The article also discusses toilet design issues related to bowel movements and offers tips for digestive health. Overall, the focus is on updated medical advice for heart risk management and practical health tips.
New research confirms that COVID-19 vaccines substantially reduce cardiovascular complications such as blood clots, stroke, arrhythmias, and heart attacks in individuals who have been vaccinated, with protective effects lasting up to a year after vaccination. While there are risks associated with vaccination, studies show that the benefits of COVID-19 vaccination, particularly in reducing cardiovascular disease, outweigh the risks for the vast majority of people, including young and otherwise healthy individuals.
A new study finds that prescription testosterone gel does not increase the risk of heart attacks or strokes in men with low levels of testosterone. However, the FDA cautions that testosterone treatment should be reserved for men with low testosterone confirmed by laboratory tests. The study included about 5,200 men, ranging in age from 45 to 80, who were assigned to use either a placebo gel or a testosterone gel, which is rubbed into the skin, daily for 22 months. The study was funded by a group of testosterone manufacturers including AbbVie, maker of Androgel, which was the product used in the study.